3 news items
Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
TAK
18 Jun 24
with a facilitated subcutaneous immunoglobulin," said Dr. Robert Hadden, MD, Consultant Neurologist, Neurology Department, King's College Hospital
Scilex Holding Announce Final Court Approval Settlement Agreement With Takeda Pharmaceuticals To Resolve The Paragraph IV Patent Infringement Lawsuit
SCLX
TAK
14 May 24
and chronic pain, today announced that the 45-day review period for the U.S. Federal Trade Commission and U.S. Department of Justice to comment
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
TAK
18 Apr 24
long-term clinical remission," said Timothy Ritter, MD, senior medical director, Department of Research and Education, GI Alliance Research
- Prev
- 1
- Next